REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/23/2026
Back to search
Official data from USPTO
NUMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NUMAB
ST13
US500000079266778Class
1, 5, 42, 44
Filing
79266778
Registration
6274672
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
02/24/2026
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
11/28/2018
Registration date
02/23/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/23/2021
Last transaction
02/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
KNIGHT, TROY FRANK
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Numab Therapeutics AG
Numab Therapeutics AG
Numab Innovation AG
Representatives
Dennis S. Prahl Ladas & Parry LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalsbiochemicalsbiological preparations and enzymes from biotechnological processes for use in industry and science; chemicalsbiochemicalsbiological preparations and enzymesantibodies and antibody fragmentsfrom biotechnological processesfor development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereofantibodies and antibody fragments for use in laboratoriesdiagnosis and analysis for scientific and research purposes; chemical and biochemical additivescarriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof
Class 5
Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases and other pathologiestreatable or improvable through use of antibodies that bind toactivate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases
Class 42
Research and development services in the field of pharmaceutical preparationsbiotechnologyantibodies and antibody fragmentsproteinsmicro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparationsbiotechnologyantibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; researchproduct development and quality control services in the field of pharmacymedical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacymedical diagnosismedical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemicalbiochemical and biotechnological analysis and research
Class 44
Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncologyoncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncologyoncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncologyoncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnosticprophylactic and therapeutic properties of drugs in the fields of immuno-oncologyoncology and immunology
Publications
History of USPTO decisions and trademark events.
40 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/31/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/27/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/13/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
06/06/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/26/2021
FIMP
FINAL DISPOSITION PROCESSED
05/26/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/23/2021
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
03/01/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
02/28/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
02/23/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/08/2020
PUBO
PUBLISHED FOR OPPOSITION
12/08/2020
GPNX
NOTIFICATION PROCESSED BY IB
12/06/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/18/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/18/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/18/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/30/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/13/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/13/2020
ALIE
ASSIGNED TO LIE
10/13/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/01/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/06/2020
GNRT
NON-FINAL ACTION E-MAILED
03/06/2020
CNRT
NON-FINAL ACTION WRITTEN
03/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2020
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
02/14/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2020
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
02/07/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/14/2019
RFNT
REFUSAL PROCESSED BY IB
10/19/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/28/2019
RFRR
REFUSAL PROCESSED BY MPU
09/28/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/18/2019
CNRT
NON-FINAL ACTION WRITTEN
09/17/2019
MAFR
APPLICATION FILING RECEIPT MAILED
09/17/2019
DOCK
ASSIGNED TO EXAMINER
09/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/13/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/05/2019
Continuous trademark protection
Get notified about every new filing that threatens NUMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.